In 1968, the contamination of cooking oil by heat-degraded polychlorinated biphenyls (PCBs) caused a case of mass poisoning, the so-called Yusho incident. The cause of Yusho disease is thought to be ingested toxic substances, including not only PCBs but also polychlorinated dibenzofuran (PCDFs) in Kanemi rice oil. We previously measured dioxins concentrations in the blood of 854 Yusho patients by annual medical examination from 2001 to 2013. We determined the concentrations of 2,3,4,7,8-PeCDF, 1,2,3,4,7,8-HxCDF, 1,2,3,6,7,8-HxCDF and 3,3',4,4',5,5'-HxCB (#169) in the blood of Yusho patients were more than double those of normal controls. In 2012, a new Yusho criteria was established. Family members living with a Yusho patient were also certified as Yusho patients and called Yusho family cohabitant patients. In this study, we compared the distribution of 2,3,4,7,8-PeCDF concentration in the blood of Yusho patients and Yusho family cohabitant patients. It was suspected that the distribution of 2,3,4,7,8-PeCDF concentration in Yusho family cohabitant patients would be lower than that of Yusho patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A phase 2, randomized, double-blind, vehicle-controlled trial of tapinarof cream in Japanese pediatric patients with atopic dermatitis.
J Dermatol
December 2024
Japan Tobacco Inc, Tokyo, Japan.
Tapinarof is a nonsteroidal, topical, aryl hydrocarbon receptor agonist approved for the treatment of atopic dermatitis (AD) in Japanese patients aged ≥12 years. We evaluated the efficacy and safety of tapinarof in Japanese pediatric patients aged 2 to 11 years with AD in a phase 2, multicenter, randomized, double-blind, vehicle-controlled trial. Eligible patients (N = 121) were randomized 1:1:1 to receive tapinarof cream 0.
View Article and Find Full Text PDFTapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials.
J Dermatol
November 2024
Japan Tobacco Inc., Tokyo, Japan.
Article Synopsis
- Tapinarof cream 1% is a nonsteroidal topical treatment evaluated in two phase 3 trials for Japanese patients aged 12 and older with atopic dermatitis (AD).
- In trial ZBB4-1, tapinarof showed significantly better outcomes, with 20.24% of patients achieving clear or almost clear skin compared to 2.24% for the vehicle; ZBB4-2 demonstrated ongoing effectiveness over 52 weeks.
- Most side effects were mild to moderate, and common issues included folliculitis, acne, and headaches, indicating that tapinarof is generally safe for long-term use in treating AD.
Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials.
J Dermatol
October 2024
Japan Tobacco Inc., Tokyo, Japan.
Article Synopsis
- - Tapinarof cream (1%) was tested for treating plaque psoriasis in two phase 3 trials involving Japanese patients, showing a significant improvement in psoriasis symptoms compared to a vehicle (inactive treatment).
- - In the first trial (ZBA4-1), 20.06% of patients using tapinarof achieved high success at week 12 compared to only 2.5% with the vehicle, while in the second trial (ZBA4-2), the treatment success rate increased to 56.3% by week 52.
- - The treatment was generally safe, with most side effects being mild or moderate, such as folliculitis and contact dermatitis, confirming tapinarof cream's efficacy and safety for
Global prevalence of oral pigmentation and its related factors: a systematic review and meta-analysis.
J Stomatol Oral Maxillofac Surg
October 2022
Research Center for Environmental Determinants of Health, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. Electronic address:
Background: Oral pigmentation is due to the accumulation of one or more pigments in tissues, causing changes in the color of the oral mucosal surfaces. Understanding the exact global prevalence of oral pigmentation and its associated factors helps researchers make the proper interventions at the right time; in this respect, the objective of the present systematic review and meta-analysis was to determine the global prevalence of oral pigmentation and its related factors.
Method: A systematic review and meta- analysis were conducted using the following databases: Magiran, SID, Scopus, Embase, PubMed, Web of Science (WoS), and Google Scholar.
Atopic Dermatitis Control Tool (ADCT): A useful tool for self-evaluation in patients with atopic dermatitis.
J Dermatol
December 2021
Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!